Enliven Therapeutics (ELVN) Assets Average (2020 - 2026)

Enliven Therapeutics has disclosed Assets Average across 7 years of filings, most recently posting $470.5 million for Q1 2026.

• Assets Average for Q1 2026 came in at $470.5 million, up 49.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $470.5 million (up 49.77% YoY), and the FY2025 annual result was $401.0 million, up 34.19% from the prior year.
• Assets Average came in at $470.5 million for Q1 2026 at Enliven Therapeutics, down from $483.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $497.4 million in Q3 2025 to a low of $61.9 million in Q3 2022.
• The 5-year median for Assets Average is $307.3 million (2024), against an average of $281.2 million.
• Across the five-year window, Assets Average slumped 31.05% in 2022 and jumped 354.51% in 2023, its largest moves.
• Enliven Therapeutics' Assets Average stood at $71.2 million in 2022, then jumped by 283.36% to $273.0 million in 2023, then grew by 15.62% to $315.6 million in 2024, then soared by 53.21% to $483.5 million in 2025, then decreased by 2.69% to $470.5 million in 2026.
• The last three Assets Average figures came in at $470.5 million (Q1 2026), $483.5 million (Q4 2025), and $497.4 million (Q3 2025), per Business Quant data.